Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.